Analytical Data
-
Gene name
HLA-A*02:01&B2M&SSX-2(KASEKIFYV) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & SSX-2 (KASEKIFYV)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&KASEKIFYV
-
Molecular Weight
40-43 kDa and 11 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HLA-A*02:01 is a highly significant class I major histocompatibility complex (MHC) molecule, playing a critical role in the immune system by presenting peptide antigens to CD8+ T cells. The β2-microglobulin (B2M) is essential for its stability and surface expression, while SSX-2 (KASEKIFYV) is an oncofetal antigen often overexpressed in various tumors, making it a target of interest in cancer immunotherapy. The combination of HLA-A*02:01, B2M, and the SSX-2 peptide provides a unique opportunity to investigate the binding affinity, stability, and immunogenicity of tumor-associated antigens. Studies on this recombinant monomer can enhance our understanding of the mechanisms underlying T-cell activation and recognition of cancer cells. Additionally, elucidating the structural dynamics of this complex could pave the way for the development of novel therapeutic vaccines and T-cell therapies targeting SSX-2-positive tumors. Furthermore, this research can contribute to the overall field of personalized cancer immunotherapy, where understanding individual T-cell responses to specific antigen-MHC complexes is crucial for effective treatment strategies. Overall, the HLA-A*02:01/B2M/SSX-2 (KASEKIFYV) recombinant protein serves as a pivotal tool in advancing cancer treatment research and improving outcomes for patients with malignancies expressing this particular antigen.
